logo-loader
viewLexaria Bioscience Corp.

Lexaria Bioscience springs for digital marketing services from the Richmond Club

The company will help Lexaria with investor presentations, articles and videos, and other digital marketing services

Contract form
Lexaria Bioscience is a Kelowna, British Columbia company with 40 patents pending around the world for disruptive drug delivery technologies

Lexaria Bioscience Corp (OTCMKTS:LXRP) (CSE:LXX), a drug delivery platform company, has decided to invest in media services for at least the next six months..

Streetwise Investors Club Inc, a Toronto-based company doing business under the name the Richmond Club, will help Lexaria with investor presentations, articles and videos, and other digital marketing services.

READ: Lexaria Bioscience shareholders approve the appointment of four directors

The deal will pay Richmond Club C$3,500 per month for a minimum of six months and will automatically be renewed unless terminated.

Lexaria Bioscience is a Kelowna, British Columbia company with 40 patents pending around the world for disruptive drug delivery technologies. A patent for DehydraTECH, which improves the taste, smell, speed and absorption of compounds, has been granted in the US and Australia.

Its shares slid 3.5% to C$1.09 on the CSE and 3.5% to US$0.84 on OTC Markets on Friday.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Lexaria Bioscience Corp.

Price: 0.39 CAD

CSE:LXX
Market: CSE
Market Cap: $34.94 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Lexaria Bio Science files patent for technology to treat...

Lexaria Bioscience (CSE: LXX-OTC: LXRP) CEO Chris Bunka joined Steve Darling from Proactive Vancouver to discuss the company has filed a patent for their DehydraTech technology for the delivery of antiviral drugs. Bunka telling Proactive this technology would potentially be used to improve...

on 04/21/2020

2 min read